Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Open accessThe DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Abstract
Alcohol use disorder (AUD) is a highly prevalent but severely under-treated disorder, with only three widely-approved pharmacotherapies. Given that AUD is a very heterogeneous disorder, it is unlikely that one single medication will be effective for all individuals with an AUD. As such, there is a need to develop new, more effective, and diverse pharmacological treatment options for AUD with the hopes of increasing utilization and improving care. In this qualitative literature review, we discuss the efficacy, mechanism of action, and tolerability of approved, repurposed, and novel pharmacotherapies for the treatment of AUD with a clinical perspective. Pharmacotherapies discussed include: disulfiram, acamprosate, naltrexone, nalmefene, topiramate, gabapentin, varenicline, baclofen, sodium oxybate, aripiprazole, ondansetron, mifepristone, ibudilast, suvorexant, prazosin, doxazosin, N-acetylcysteine, GET73, ASP8062, ABT-436, PF-5190457, and cannabidiol. Overall, many repurposed and novel agents discussed in this review demonstrate clinical effectiveness and promise for the future of AUD treatment. Importantly, these medications also offer potential improvements towards the advancement of precision medicine and personalized treatment for the heterogeneous AUD population. However, there remains a great need to improve access to treatment, increase the menu of approved pharmacological treatments, and de-stigmatize and increase treatment-seeking for AUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similarly, the efficacy of naltrexone and acamprosate are also suspected and inconclusive for preventing relapse in AUD [55].”
From Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial (2023) · cites this paper as [55]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reductions in SUD severity were also found, suggesting improvements in SUD-related consequences and functioning.”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While alcohol abstinence is desirable as the ultimate outcome of AUD treatment, only 16% of patients with AUD are able to achieve abstinence [55].”
From Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial (2023) · cites this paper as [55]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a type of alcohol antagonist, disulfiram causes patients to experience strong physical discomfort after ingesting a small amount of alcohol, which may place patient at risk of the disulfiram-ethanol interaction reaction, at high risk of non-compliance and cannot effectively reduce craving, so it is basically not a preferred treatment for AUD unless supervised treatment with disulfiram can be”
From Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial (2023) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The US Food and Drug Administration (FDA) has approved three drugs for abstinence: disulfiram, naltrexone and acamprosate.”
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–318 of 318
Moderation of Prazosin’s Efficacy by Alcohol Withdrawal Symptoms
Sinha, R., Wemm, S., Fogelman, N., Milivojevic, V., Morgan, P. M., Angarita, G. A., Hermes, G., & Fox, H. C. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20050609 · Cited by 54 · cited 1×
“, reduced craving and heavy-drinking days; improved mood symptoms) [210].”
BackgroundRodd, Z. A., Bell, R. L., Oster, S. M., Toalston, J. E., Pommer, T. J., McBride, W. J., & Murphy, J. M. (2010) · Alcohol · doi:10.1016/j.alcohol.2010.01.002 · Cited by 51
Hargreaves, G. A., & McGregor, I. S. (2007) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00485.x · Cited by 51
EFFECTS OF ARIPIPRAZOLE ON ALCOHOL INTAKE IN AN ANIMAL MODEL OF HIGH-ALCOHOL DRINKING
Ingman, K., KUPILA, J., Hyytiä, P., & Korpi, E. R. (2006) · Alcohol and Alcoholism · doi:10.1093/alcalc/agl037 · Cited by 50 · cited 1×
“Preclinically, aripiprazole has been shown to reduce ethanol-induced place preference and decrease drinking behaviors in mice [151], as well as reducing alcohol consumption in alcohol-preferring rats [152, 153].”
BackgroundUbaldi, M., Giordano, A., Severi, I., Li, H., Kallupi, M., de Guglielmo, G., Ruggeri, B., Stopponi, S., Ciccocioppo, R., & Cannella, N. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.021 · Cited by 49
Leggio, L. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.3.1429490 · Cited by 48 · cited 1×
“Ghrelin signaling is required for stimulation of the reward system by alcohol, and higher ghrelin levels are associated with higher self-reported measures of alcohol craving [263].”
BackgroundIsrael, Y., Quintanilla, M. E., Ezquer, F. E., Morales, P., Santapau, D., Berríos‐Cárcamo, P., Ezquer, M., Olivares, B., & Herrera‐Marschitz, M. (2019) · Addiction Biology · doi:10.1111/adb.12853 · Cited by 48 · cited 1×
“NAC and aspirin co-administration also reduced ethanol intake and relapse binge drinking in ethanol-preferring rats [221].”
BackgroundHaass-Koffler, C. L., Goodyear, K., Zywiak, W. H., Magill, M., Eltinge, S. E., Wallace, P. M., Long, V. M., Jayaram-Lindström, N., Swift, R. M., Kenna, G. A., et al. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.03.016 · Cited by 47 · cited 1×
“However, further examination of clinical moderators revealed that doxazosin significantly reduced drinks per week and heavy-drinking days among individuals with higher family history of AUD and higher standing diastolic blood pressure [209].”
BackgroundDevoto, P., Flore, G., Saba, P., Cadeddu, R., & Gessa, G. L. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2447-5 · Cited by 46 · cited 1×
“Disulfiram may also act on dopamine systems, as its major metabolite inhibits the enzyme dopamine betahydroxylase (DBH), which aids in metabolizing dopamine into noradrenaline [22, 26, 27].”
BackgroundTopiramate for Alcohol Dependence
Olmsted, C. L., & Kockler, D. R. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l157 · Cited by 46 · cited 1×
“Topiramate has already been demonstrably effective in clinical applications across a number of drinking outcomes [121], but longer-term trials of topiramate are recommended to optimize dose and duration, as well as further exploring side effects.”
BackgroundThe Neuroimmune Basis of Excessive Alcohol Consumption
Mayfield, J., & Harris, R. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.177 · Cited by 45
Montesinos, J., Gil, A., & Guerri, C. (2017) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13416 · Cited by 45
Mocelin, R., Marcon, M., Araújo, A. S. D. R., Herrmann, A. P., & Piato, Â. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.03.014 · Cited by 44 · cited 1×
“Preclinically, NAC has been shown to reduce withdrawal effects [217], block the development of behavioral sensitization to alcohol [218], and attenuate biological adaptations induced by alcohol cessation (i.”
BackgroundZonisamide decreases ethanol intake in rats and mice
Knapp, C. M., Mercado, M., Markley, T. L., Crosby, S. J., Ciraulo, D. A., & Kornetsky, C. H. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.04.001 · Cited by 43
Effect of topiramate treatment on ethanol consumption in rats
Breslin, F. J., Johnson, B. A., & Lynch, W. J. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1683-4 · Cited by 43
Effects of prazosin on the dopaminergic neurotransmission in rat brain
Sommermeyer, H., Frielingsdorf, J., & Knorr, A. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00062-p · Cited by 43 · cited 1×
“Prazosin and doxazosin are alpha-1 adrenergic receptor antagonists with similar chemical structures that can readily cross the blood-brain barrier and block noradrenergic excitation of the mesolimbic dopaminergic system [197, 198].”
BackgroundShalaby, H. N., El-Tanbouly, D. M., & Zaki, H. F. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.05.022 · Cited by 43
Naltrexone long-acting formulation in the treatment of alcohol dependence.
Johnson, B. A. (2007) · PubMed Central · Cited by 42
Caputo, F., Francini, S., Stoppo, M., Lorenzini, F., Vignoli, T., Del Re, A., Comaschi, C., Leggio, L., Addolorato, G., Zoli, G., et al. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108094620 · Cited by 42 · cited 1×
“SMO craving and abuse potential may limit its use; however, at therapeutic doses, SMO abuse seems to be a relatively infrequent phenomenon among patients without psychiatric comorbidities or poly-drug use [96, 100, 105].”
BackgroundPrommer, E. (2015) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909115612800 · Cited by 42
Evaluation of N-acetylcysteine on ethanol self-administration in ethanol-dependent rats
Lebourgeois, S., González‐Marín, M. C., Antol, J., Naassïla, M., & Vilpoux, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.010 · Cited by 42 · cited 2×
“Additionally, NAC reduced ethanol-seeking and self-administration in rodents [215, 216].”
BackgroundO'Neil, M. L., Beckwith, L. E., Kincaid, C. L., & Rasmussen, D. D. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01884.x · Cited by 41 · cited 1×
“Doxazosin decreased voluntary alcohol intake in alcohol-preferring rats in a dose-dependent manner, and this effect was likely not due to general motor impairment [204].”
BackgroundStevenson, J. R., Francomacaro, L. M., Bohidar, A. E., Young, K., Pesarchick, B. F., Buirkle, J. M., McMahon, E. K., & O'Bryan, C. M. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.12.017 · Cited by 40
Potential of GABAB Receptor Positive Allosteric Modulators in the Treatment of Alcohol Use Disorder
Maccioni, P., & Colombo, G. (2019) · CNS Drugs · doi:10.1007/s40263-018-0596-3 · Cited by 40 · cited 1×
“In comparison to the drawbacks presented by GABAB agonists like baclofen and SMO, positive allosteric modulators (PAMs) at this receptor present a potential alternative [252].”
BackgroundYang, Y., Lee, S. M., Imamura, F., Gowda, K., Amin, S., & Mailman, R. B. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0312-1 · Cited by 39
Miranda, R., O’Malley, S. S., Padovano, H. T., Wu, R., Falk, D. E., Ryan, M. L., Fertig, J. B., Chun, T. H., Muvvala, S. B., & Litten, R. Z. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14352 · Cited by 39 · cited 1×
“However, a 12-week RCT (N = 160) found no effect of varenicline over placebo on heavy-drinking days [143], and a recent 6-week human laboratory study in 47 participants found that varenicline did not significantly attenuate cueinduced alcohol craving relative to placebo [144].”
BackgroundThe Role of Pharmacotherapy in the Treatment of Adolescent Substance Use Disorders
Hammond, C. J. (2016) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2016.05.004 · Cited by 38 · cited 1×
“Of note, NAC is currently being tested in adolescent AUD, a unique prospect as no other AUD pharmacotherapies are yet approved for adolescents [225].”
BackgroundFarokhnia, M., Deschaine, S. L., Sadighi, A., Farinelli, L. A., Lee, M. R., Akhlaghi, F., & Leggio, L. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0287-y · Cited by 38 · cited 1×
“This heterogeneity is an important factor to take into account when considering baclofen as an AUD treatment [92].”
BackgroundLei, K., Kwok, C., Darevsky, D. M., Wegner, S. A., Yu, J.-H., Nakayama, L., Pedrozo, V., Anderson, L., Ghotra, S., Fouad, M., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00088 · Cited by 37
Suppressing Effect of Baclofen on Multiple Alcohol-Related Behaviors in Laboratory Animals
Colombo, G., & Gessa, G. L. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00475 · Cited by 36
Kampman, K. M., Pettinati, H. M., Lynch, K. G., Xie, H., Dackis, C., Oslin, D. W., Sparkman, T., Sharkoski, T., & O'Brien, C. P. (2009) · Addictive Behaviors · doi:10.1016/j.addbeh.2009.03.014 · Cited by 35
Rose, J. L., Karkhanis, A. N., Steiniger‐Brach, B., & Jones, S. R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081216 · Cited by 35 · cited 1×
“Via its kappa agonist activity, particularly centered in dopaminergic nucleus accumbens circuitry, nalmefene may reduce motivation for self-administration and withdrawal-induced alcohol consumption [69, 70].”
BackgroundAnton, R. F., Schacht, J. P., Voronin, K. E., & Randall, P. K. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13417 · Cited by 35 · cited 2×
“Some of these appear to have particular promise in specific cases, such as varenicline’s use for nicotine and alcohol co-users [147], baclofen for individuals with liver disease [93], and aripiprazole for more impulsive individuals [156].”
BackgroundPrazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse
Froehlich, J. C., Hausauer, B., Fischer, S., Wise, B., & Rasmussen, D. D. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12789 · Cited by 34 · cited 1×
“In addition, prazosin treatment prevented yohimbine stress-induced reinstatement of ethanol seeking [202] and attenuated ethanol intake during relapse in alcohol-preferring rats [203].”
BackgroundCaputo, F., Francini, S., Brambilla, R., Vigna‐Taglianti, F., Stoppo, M., Re, A. D., Leggio, L., Addolorato, G., Zoli, G., & Bernardi, M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.12.005 · Cited by 34 · cited 1×
“Indeed, in another clinical study with a sample of 48 participants, craving for SMO was observed in 10% of participants with psychiatric comorbidities [101], indicating that patients may be at risk of developing craving for and abusing SMO.”
BackgroundEffects of Aripiprazole on Subjective and Physiological Responses to Alcohol
Kranzler, H. R., Covault, J., Pierucci‐Lagha, A., Chan, G., Douglas, K., Arias, A. J., & Oncken, C. A. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00608.x · Cited by 34 · cited 1×
“, subjective response to alcohol), including reducing the euphoric effects of alcohol and increasing sedative effects [154].”
BackgroundMurai, N., Kondo, Y., Akuzawa, S., Mihara, T., Shiraishi, N., Kakimoto, S., & Matsumoto, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172750 · Cited by 34 · cited 1×
“One such novel GABAB PAM, ASP8062, appears particularly promising as it has been shown to significantly increase the affinity and efficacy of endogenous GABA binding in human and rat GABAB receptors in vitro and with oral administration in an in vivo rodent model of fibromyalgia, demonstrating the ability of oral form…”
BackgroundGjoni, T., Desrayaud, S., Imobersteg, S., & Urwyler, S. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03660.x · Cited by 33 · cited 1×
“By binding to a different, non-competitive allosteric site on the GABAB receptor, PAMs allow endogenous GABA, binding at its original orthosteric site, to retain its potency and efficacy, reducing the risk of tolerance development and side effects [253, 254].”
BackgroundChoosing the right medication for the treatment of alcoholism
Pettinati, H. M., & Rabinowitz, A. R. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0040-0 · Cited by 33
Ozburn, A. R., Metten, P., Potretzke, S., Townsley, K. G., Blednov, Y. A., & Crabbe, J. C. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14269 · Cited by 33 · cited 1×
“Preclinical studies of gabapentin’s effects on ethanol consumption have shown mixed results, with some studies finding that gabapentin reduced ethanol intake in alcoholdependent rodents [123] and others finding that it increased self-administration and binge-like drinking [124, 125].”
ResultA Rational Approach to the Pharmacotherapy of Alcohol Dependence
Petrakis, I. L. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248602.68607.81 · Cited by 32
Advances in Pharmacotherapy Development: Human Clinical Studies
Litten, R. Z., Falk, D. E., Ryan, M. L., Fertig, J. B., & Leggio, L. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_79 · Cited by 32
Vengeliene, V., Takahashi, T. T., Драволина, О. А., Владимировна, Б. И., Zvartau, E. E., Bespalov, A., & Spanagel, R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4893-9 · Cited by 32
Effects of prazosin and doxazosin on yohimbine-induced reinstatement of alcohol seeking in rats
Funk, D. R., Coen, K. M., Tamadon, S., Li, Z., Loughlin, A., & Lê, A. D. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4273-2 · Cited by 31 · cited 1×
“In addition, prazosin treatment prevented yohimbine stress-induced reinstatement of ethanol seeking [202] and attenuated ethanol intake during relapse in alcohol-preferring rats [203].”
BackgroundHaass‐Koffler, C. L., Goodyear, K., Zywiak, W. H., Leggio, L., Kenna, G. A., & Swift, R. M. (2017) · Alcohol and Alcoholism · doi:10.1093/alcalc/agx108 · Cited by 31 · cited 1×
“However, another recent five-week study assessing topiramate, aripiprazole, and their combination with 90 participants found that effects on drinking reduction were due to topiramate, while no significant findings were seen for aripiprazole for any outcomes [159].”
Background(2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000170859.83605.81 · Cited by 31 · cited 1×
“A six-month multisite trial of 380 mg injectable naltrexone in 624 patients with alcohol dependence found significant reductions in heavy-drinking days versus placebo [61].”
BackgroundSuvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial
Campbell, E. J., Norman, A. F., Bonomo, Y. A., & Lawrence, A. J. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146597 · Cited by 30 · cited 1×
“Given the effectiveness of orexin antagonists in reducing alcohol drinking at the preclinical level of analysis, suvorexant has garnered interest as a drug that can be repurposed to treat AUD [239].”
BackgroundBurnette, E. M., Ray, L. A., Irwin, M. R., & Grodin, E. N. (2021) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14696 · Cited by 30 · cited 1×
“Another recent 2-week RCT enrolling 52 participants found that ibudilast also significantly decreased the odds of heavy drinking during the trial by 45% compared to placebo and attenuated neural response to alcohol cues in the ventral striatum [193, 194].”
BackgroundSelf-citationMaremmani, A. G. I., Pani, P. P., Rovai, L., Pacini, M., Dell’Osso, L., & Maremmani, I. (2011) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph8072816 · Cited by 29 · cited 1×
“A study of 52 subjects with chronic, treatment-resistant alcohol dependence found that participants stayed in treatment significantly longer when SMO was co-administered with disulfiram than with SMO alone [103].”
BackgroundIbudilast for the treatment of drug addiction and other neurological conditions
Johnson, K. W., Matsuda, K., & Iwaki, Y. (2014) · Clinical Investigation · doi:10.4155/cli.14.8 · Cited by 29 · cited 1×
“As increases in inflammation are seen in AUD [186], the effects of ibudilast in treating AUD are thought to be driven by its anti-inflammatory and proneurotrophic qualities [187].”
BackgroundKong, J., Chuddy, J., Stock, I. A., Loria, P. M., Straub, S. V., Vage, C., Cameron, K. O., Bhattacharya, S. K., Lapham, K., McClure, K. F., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13439 · Cited by 29 · cited 1×
“PF-5190457 is a ghrelin receptor inverse agonist that inhibits GHS-R1a constitutive activity as well as blocking its activation by ghrelin [271].”
BackgroundMorais‐Silva, G., Alves, G. C., & Marin, M. T. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.009 · Cited by 29
Addolorato, G., Lesch, O., Maremmani, I., Walter, H., Nava, F. A., Raffaillac, Q., & Caputo, F. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1709821 · Cited by 29 · cited 3×
“SMO craving and abuse potential may limit its use; however, at therapeutic doses, SMO abuse seems to be a relatively infrequent phenomenon among patients without psychiatric comorbidities or poly-drug use [96, 100, 105].”
BackgroundFinn, S. W., Lundin, A., Sjöqvist, H., & Danielsson, A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108964 · Cited by 29 · cited 1×
“The European Medicines Agency (EMA) similarly recognizes only these same three medications, as well as nalmefene, as established pharmacotherapies for AUD [12].”
BackgroundTolerance to Disulfiram Induced by Chronic Alcohol Intake in the Rat
Tampier, L., Quintanilla, M. E., & Israel, Y. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00658.x · Cited by 28
Mohapatra, S., & Rath, N. R. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.1.68 · Cited by 26 · cited 2×
“Disulfiram may also act on dopamine systems, as its major metabolite inhibits the enzyme dopamine betahydroxylase (DBH), which aids in metabolizing dopamine into noradrenaline [22, 26, 27].”
BackgroundBusch, A. C., Denduluri, M., Glass, J., Hetzel, S., Gugnani, S. P., Gassman, M., Krahn, D., Deyo, B., & Brown, R. (2017) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13410 · Cited by 26 · cited 1×
“Oral and injectable naltrexone show similar decreases in likelihood of binge drinking [65] and both are generally well tolerated, with fairly mild side effects [66].”
BackgroundBack, S. E., Gray, K. M., Ana, E. J. S., Jones, J. L., Jarnecke, A. M., Joseph, J. E., Prisciandaro, J. J., Killeen, T. K., Brown, D. G., Taimina, L., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.105961 · Cited by 26 · cited 1×
“Additional clinical trials will also examine the effectiveness of NAC in adolescent and adult samples of AUD ([224], NCT03707951).”
BackgroundWhat the alcohol doctor ordered from the neuroscientist
Heilig, M., & Leggio, L. (2016) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.07.023 · Cited by 25 · cited 1×
“It is likely that personalized treatment approaches will need to account for multiple factors to truly tailor treatments to individual patients [294].”
BackgroundMaccioni, P., Colombo, G., Lorrai, I., Zaru, A., Carai, M. A. M., Gessa, G. L., Brizzi, A., Mugnaini, C., & Corelli, F. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4644-3 · Cited by 25
Haass‐Koffler, C. L., Goodyear, K., Long, V. M., Tran, H. H., Loche, A., Cacciaglia, R., Swift, R. M., & Leggio, L. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.07.031 · Cited by 25
Vanderkam, P., Solinas, M., Ingrand, I., Doux, N., Ebrahimighavam, S., Jaafari, N., & Lafay‐Chebassier, C. (2021) · Addiction · doi:10.1111/add.15265 · Cited by 25 · cited 1×
“A small meta-analysis of 6 studies with a total of 319 participants tested the effectiveness of drugs acting on adrenergic receptors for AUD and found a significant treatment effect of prazosin and doxazosin on alcohol consumption but not abstinence [211].”
BackgroundDonoghue, K., Rose, A., Coulton, S., Milward, J., Reed, K., Drummond, C., & Little, H. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0757-1 · Cited by 23 · cited 1×
“A two-week Phase 4 RCT examining the effects of mifepristone on cognition in AUD was recently conducted, but recruitment challenges rendered the results inconclusive [181, 182].”
Background&NA; (2001) · Survey of Anesthesiology · doi:10.1097/00132586-200104000-00054 · Cited by 23
Umathe, S. N., Bhutada, P., Raut, V. S., Jain, N. S., & Mundhada, Y. R. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283242ff4 · Cited by 21 · cited 1×
“locomotor stimulant effects of ethanol [167] and reduce voluntary ethanol intake, preference, and withdrawal seizures in rodent models [168, 169].”
BackgroundAnti-Alcohol and Anxiolytic Properties of a New Chemical Entity, GET73
Loche, A., Simonetti, F., Lobina, C., Carai, M. A. M., Colombo, G., Castelli, M. P., Barone, D., & Cacciaglia, R. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00008 · Cited by 21 · cited 2×
“These effects are similar to those seen with GHB administration [247]; however, GET73 was shown not to bind to either high- or low-affinity GHB binding sites in rat cortical membranes [246].”
BackgroundHarm Reduction as “Continuum Care” in Alcohol Abuse Disorder
Maremmani, I., Cibin, M., Pani, P., Rossi, A., & Turchetti, G. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph121114828 · Cited by 21
Katz, D. A., Locke, C. S., Liu, W., Zhang, J., Achari, R., Wesnes, K. A., & Tracy, K. A. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12996 · Cited by 21 · cited 1×
“ABT-436 has been shown to attenuate basal HPA axis activity in humans [243].”
BackgroundSun, H., Yee, K. L., Gill, S., Liu, W., Li, X., Panebianco, D. L., Mangin, E. C., Morrison, D., McCrea, J. B., Wagner, J. A., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609015 · Cited by 21 · cited 1×
“The sedative effects of suvorexant are of notable concern, particularly if individuals engage in alcohol drinking during treatment [240].”
BackgroundVarenicline modulates ethanol and saccharin consumption in adolescent male and female C57BL/6J mice
Kamens, H. M., Silva, C. P., Peck, C., & Miller, C. N. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.07.020 · Cited by 21
Maccioni, P., Lorrai, I., Contini, A., Leite‐Morris, K. A., & Colombo, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.012 · Cited by 21
Witkiewitz, K. A., Morris, J. K., & Tucker, J. A. (2021) · Addiction · doi:10.1111/add.15429 · Cited by 21
Chester, J. A., Grahame, N. J., Li, T., Lumeng, L., & Froehlich, J. C. (2001) · Behavioural Pharmacology · doi:10.1097/00008877-200111000-00015 · Cited by 20
Calleja‐Conde, J., Echeverry‐Alzate, V., Giné, E., Bühler, K., Nadal, R. A., Maldonado, R. J., de Fonseca, F. R., Gual, A., & López‐Moreno, J. A. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13526 · Cited by 20
Mifepristone decreases chronic voluntary ethanol consumption in Rhesus macaques
Jimenez, V. A., Walter, N. A. R., Shnitko, T. A., Newman, N., Diem, K., Vanderhooft, L., Hunt, H., & Grant, K. A. (2020) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000169 · Cited by 20 · cited 1×
“Recent preclinical research in primates has shown mixed results, such that mifepristone was shown to decrease chronic voluntary alcohol consumption in rhesus macaques at doses of 30 and 56 mg/kg per day [179], but had no effect on alcohol-seeking or self-administration in baboons at slightly lower doses of 10–30 mg/kg…”
ResultGET73 Prevents Ethanol-Induced Neurotoxicity in Primary Cultures of Rat Hippocampal Neurons
Tomasini, M. C., Borelli, A. C., Beggiato, S., Tanganelli, S., Loche, A., Cacciaglia, R., Ferraro, L., & Antonelli, T. (2015) · Alcohol and Alcoholism · doi:10.1093/alcalc/agv094 · Cited by 19 · cited 12×
“A translational study examining GET73-alcohol interactions found that neither 30 nor 100 mg/kg GET73 administered in rats (equivalent to doses employed in humans) potentiated alcohol-induced intoxication.”
BackgroundInfluentialJacobsen, J. H. W., Buisman‐Pijlman, F. T. A., Mustafa, S., Rice, K. C., & Hutchinson, M. R. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.028 · Cited by 19
Walzer, M., Marek, G. J., Wu, R., Nagata, M., & Han, D. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.766 · Cited by 19 · cited 7×
“Two Phase I clinical trials with a combined total of 112 participants evaluated single ascending doses and multiple ascending doses of ASP8062, respectively [260].”
BackgroundInfluentialAlcohol use disorder severity moderates clinical response to varenicline
Donato, S., Green, R., & Ray, L. A. (2021) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14674 · Cited by 19 · cited 1×
“Moderator analyses of data collected in the above multisite trial [142] indicated that varenicline was more efficacious in reducing drinking among smokers who also reduced their cigarette smoking [147] and among individuals with lower severity of AUD, such that that varenicline significantly reduced percent heavy-drin…”
BackgroundSelf-citationAcamprosate Suppresses Ethanol-Induced Place Preference in Mice With Ethanol Physical Dependence
Kurokawa, K., Mizuno, K., Shibasaki, M., Higashioka, M., Oka, M., Hirouchi, M., & Ohkuma, S. (2013) · Journal of Pharmacological Sciences · doi:10.1254/jphs.13056fp · Cited by 18
Patkar, O. L., Belmer, A., Tarren, J. R., Holgate, J. Y., & Bartlett, S. E. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.09.048 · Cited by 18
Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence
Mannucci, C., Pichini, S., Spagnolo, E. V., Calapai, F., Gangemi, S., Navarra, M., & Calapai, G. (2017) · Current Drug Metabolism · doi:10.2174/1389200219666171207122227 · Cited by 18 · cited 1×
“It was shown to reduce relapses when administered with naltrexone and escitalopram [102].”
BackgroundDrinking Levels and Profiles of Alcohol Addicted Rats Predict Response to Nalmefene
Foo, J. C., Vengeliene, V., Noori, H. R., Yamaguchi, I., Morita, K., Nakamura, T., Yamamoto, Y., & Spanagel, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00471 · Cited by 18
Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol
Stoops, W. W., Strickland, J. C., Hays, L. R., Rayapati, A. O., Lile, J. A., & Rush, C. R. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173037 · Cited by 18 · cited 2×
“However, a recent 5-day human laboratory study (N = 9) found that NAC did not attenuate alcohol self-administration [212].”
BackgroundFentress, T. S. P., Wald, S., Brah, A., Leemon, G., Reyes, R., Alkhamees, F., Kramer, M., Taylor, E. M., Wildhood, M., Frohe, T., et al. (2021) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000470 · Cited by 18 · cited 1×
“Not all individuals with AUD consider abstinence to be a goal of their recovery; only 2–6% of goals set in patient-driven treatment center on attaining alcohol abstinence [17].”
BackgroundBesheer, J., Frisbee, S., Randall, P. A., Jaramillo, A. A., & Masciello, M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.09.027 · Cited by 17 · cited 1×
“Preclinical studies of gabapentin’s effects on ethanol consumption have shown mixed results, with some studies finding that gabapentin reduced ethanol intake in alcoholdependent rodents [123] and others finding that it increased self-administration and binge-like drinking [124, 125].”
ResultShibasaki, M., Kurokawa, K., Mizuno, K., & Ohkuma, S. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11201fp · Cited by 17 · cited 1×
“Preclinically, aripiprazole has been shown to reduce ethanol-induced place preference and decrease drinking behaviors in mice [151], as well as reducing alcohol consumption in alcohol-preferring rats [152, 153].”
BackgroundKenna, G. A., Leggio, L., & Swift, R. M. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1042 · Cited by 17 · cited 1×
“Additionally, this trial provided no evidence that the side effects of the two medications are additive, indicating that the combination is generally safe and well tolerated [158].”
BackgroundEffect of the threat of a disulfiram–ethanol reaction on cue reactivity in alcoholics
Skinner, M. D., Coudert, M., Berlin, I., Passeri, E., Michel, L., & Aubin, H.-J. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.06.011 · Cited by 17 · cited 1×
“Research showed that placebo-treated individuals showed decreases in cue-reactivity to alcohol stimuli in a sample of 38 participants [30], and experiencing an acetaldehyde reaction did not necessarily improve treatment response in a sample of 46 participants [31].”
BackgroundMutschler, J., Dirican, G., Funke, S., Obermann, C., Grosshans, M., Mann, K. F., Kiefer, F., & Diehl, A. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3182216fd5 · Cited by 17 · cited 1×
“Research showed that placebo-treated individuals showed decreases in cue-reactivity to alcohol stimuli in a sample of 38 participants [30], and experiencing an acetaldehyde reaction did not necessarily improve treatment response in a sample of 46 participants [31].”
Backgroundγ-Hydroxybutyric acid (GHB) suppresses alcohol's motivational properties in alcohol-preferring rats
Maccioni, P., Pes, D., Fantini, N., Carai, M. A. M., Gessa, G. L., & Colombo, G. (2008) · Alcohol · doi:10.1016/j.alcohol.2008.01.001 · Cited by 16
Froehlich, J. C., Fischer, S. M., Dilley, J. E., Nicholson, E. R., Smith, T. N., Filosa, N. J., & Rademacher, L. C. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13157 · Cited by 16 · cited 1×
“Additionally, the combination of varenicline and naltrexone decreased alcohol drinking more effectively than either drug on its own [141].”
BackgroundJohansen, K. G. V., Tarp, S., Astrup, A. V., Lund, H., Pagsberg, A. K., & Christensen, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183821 · Cited by 16
Jacobsen, J. H. W., Buisman‐Pijlman, F. T. A., Mustafa, S., Rice, K. C., & Hutchinson, M. R. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.08.021 · Cited by 16
Chartier, M., Tannous, S., Benturquia, N., Labat, L., Reis, R., Risède, P., Chevillard, L., & Mégarbane, B. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy073 · Cited by 16 · cited 1×
“Tolerance to baclofen may also develop with chronic administration [89, 90].”
BackgroundBaclofen and alcohol in France
Naudet, F., & Braillon, A. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30419-x · Cited by 16 · cited 1×
“It was approved for treatment of AUD in France in 2018 [78] and has been used off-label for AUD for over a decade in other countries, especially other European countries and Australia [79, 80].”
MethodRoila, F., Tonato, M., Basurto, C., Sergio Bracarda, A., Sassi, M., Lupattelli, M., Picciafuoco, M., Ballatori, E., & Favero, A. D. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80255-2 · Cited by 16
McDonough, M., & Crowley, P. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.063 · Cited by 15 · cited 1×
“Of note, naltrexone is contraindicated for patients with acute hepatitis or liver failure, and should be “carefully considered” in patients with acute liver disease [67], potentially limiting its use in the alcohol-associated liver disease (AALD) population.”
BackgroundEvaluation of mifepristone effects on alcohol-seeking and self-administration in baboons.
Holtyn, A. F., & Weerts, E. M. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000246 · Cited by 15 · cited 1×
“Recent preclinical research in primates has shown mixed results, such that mifepristone was shown to decrease chronic voluntary alcohol consumption in rhesus macaques at doses of 30 and 56 mg/kg per day [179], but had no effect on alcohol-seeking or self-administration in baboons at slightly lower doses of 10–30 mg/kg…”
ResultNirogi, R. V. S., Kandikere, V. N., Jayarajan, P., Bhyrapuneni, G., Saralaya, R., Muddana, N., & Abraham, R. (2013) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2012.730590 · Cited by 14 · cited 1×
“Preclinically, aripiprazole has been shown to reduce ethanol-induced place preference and decrease drinking behaviors in mice [151], as well as reducing alcohol consumption in alcohol-preferring rats [152, 153].”
BackgroundDonoghue, K., Rose, A. K., Coulton, S., Coleman, R., Milward, J., Phillips, T., Drummond, C., & Little, H. J. (2020) · Trials · doi:10.1186/s13063-020-04726-z · Cited by 14
Haass‐Koffler, C. L., Goodyear, K., Loche, A., Long, V. M., Lobina, C., Tran, H. H., Cacciaglia, R., Swift, R. M., Colombo, G., & Leggio, L. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117746904 · Cited by 13 · cited 1×
“Additionally, GET73 administered both in the presence and absence of alcohol was well tolerated in two samples of 14 and 11 participants, with no severe adverse events and no difference in adverse events [249].”
BackgroundLopez, M. F., Reasons, S. E., Carper, B. A., Nolen, T. L., Williams, R. L., & Becker, H. C. (2020) · Alcohol · doi:10.1016/j.alcohol.2020.07.005 · Cited by 13 · cited 1×
“Further, doxazosin significantly reduced voluntary ethanol intake in a rodent model of AUD and stress exposure [205].”
BackgroundKostowski, W., Bisaga, A. M., Jankowska, E. A., & Krząścik, P. (1994) · PubMed · Cited by 12
Comparison between baclofen and topiramate in alcohol dependence: A prospective study
Kapoor, A., Jose, N., Yadav, P., & Mahla, V. (2019) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_57_19 · Cited by 12 · cited 1×
“, 33% of participants receiving topiramate dropped out of the study vs 24% with baclofen) than topiramate [119].”
BackgroundTopiramate in the treatment of antipsychotic-induced hyperprolactinemia
Huang, Y., Peng, M., & Zhu, G. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109607 · Cited by 11 · cited 11×
“However, the drug is thought to inhibit glutamate α-amino 3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) and kainate receptors [108–110] and L-type calcium channels [111], as well as enhance the inhibitory activity of GABA [109].”
BackgroundInfluentialSedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment.
Santos, C. D., Olmedo, R. E., & Kim, J. J. (2017) · PubMed · Cited by 10
Haass‐Koffler, C. L., Perciballi, R., Magill, M., Loche, A., Cacciaglia, R., Leggio, L., & Swift, R. M. (2021) · Psychopharmacology · doi:10.1007/s00213-021-06008-1 · Cited by 10
Macaluso, M., Flynn, A., & Preskorn, S. (2016) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000157 · Cited by 9 · cited 1×
“Of note, long-term use of antipsychotics like aripiprazole may be associated with more severe adverse effects such as tardive dyskinesia, with risk factors including older age and female sex [161, 162].”
BackgroundColombo, G., Carai, M. A. M., & Gessa, G. L. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00095 · Cited by 9 · cited 1×
“These effects are similar to those seen with GHB administration [247]; however, GET73 was shown not to bind to either high- or low-affinity GHB binding sites in rat cortical membranes [246].”
BackgroundNalmefene for alcohol dependence: a NICE decision?
Naudet, F., Fitzgerald, N., & Braillon, A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30356-x · Cited by 9
Leggio, L., & Litten, R. Z. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01142-y · Cited by 9 · cited 1×
“of AUD—as well as its optimal dosage—continues to be debated [95].”
BackgroundSerum dopamine-β-Hydroxylase activity and alcohol withdrawal symptoms
Bagdy, G., & Arató, M. (1987) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(87)90086-x · Cited by 8
Commentary: Doxasozin for Alcoholism
Leggio, L., & Kenna, G. A. (2012) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12064 · Cited by 8 · cited 1×
“Prazosin and doxazosin are alpha-1 adrenergic receptor antagonists with similar chemical structures that can readily cross the blood-brain barrier and block noradrenergic excitation of the mesolimbic dopaminergic system [197, 198].”
Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series
Caputo, F., Maremmani, A. G. I., Addolorato, G., Domenicali, M., Zoli, G., d’Amore, A., Maremmani, I., & Bernardi, M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116629126 · Cited by 8 · cited 14×
“Overall, the effectiveness of SMO lies largely in reducing withdrawal symptoms and increasing abstinence rates.”
BackgroundInfluentialA Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution
Heitzmann, E., Javelot, H., Weiner, L., & Michel, B. (2016) · Case Reports in Psychiatry · doi:10.1155/2016/7031245 · Cited by 8 · cited 1×
“Of note, long-term use of antipsychotics like aripiprazole may be associated with more severe adverse effects such as tardive dyskinesia, with risk factors including older age and female sex [161, 162].”
BackgroundBeggiato, S., Borelli, A. C., Tomasini, M. C., Castelli, M. P., Pintori, N., Cacciaglia, R., Loche, A., & Ferraro, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00327 · Cited by 8
Role of Lateral Hypothalamic Orexin (Hypocretin) Neurons in Alcohol Use and Abuse: Recent Advances
Walker, L. C., Ch’ng, S. S., & Lawrence, A. J. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0069-7 · Cited by 7 · cited 1×
“The orexin/hypocretin system is well known for its role in sleep-wake regulation but has more recently been implicated in AUD [226].”
Background
Cited by
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Dharavath, R. N., Pina‐Leblanc, C., Tang, V. M., Sloan, M. E., Nikolova, Y. S., Pangarov, P., Ruocco, A. C., Shield, K. D., Voineskos, D., Blumberger, D. M., et al. (2023) · Frontiers in Neural Circuits · doi:10.3389/fncir.2023.1218737 · Cited by 92
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
van der Pol, K. H., Aljofan, M., Blin, O., Cornel, J. H., Rongen, G. A. P. J. M., Woestelandt, A.-G. B., & Spedding, M. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00816-6 · Cited by 68
Baclofen for alcohol use disorder
Agabio, R., Saulle, R., Rösner, S., & Minozzi, S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub3 · Cited by 77
Metadata
- Authors
- Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A.
- Affiliations
- University of California, Los Angeles (US)
- Los Angeles County Department of Public Health (US)
- Corresponding author
- Ray, Lara A.
- ORCID
- Venue
- Drugs
- Published
- 2022-02
- Volume
- 82
- Issue
- 3
- Pages
- 251-274
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC8888464
- OpenAlex
- W4210944481
- Cited by
- 169
- References
- 318
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 52 · 2023: 35 · 2022: 14
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor, 7 d)
- Locations
- Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (K24AA025704, F31AA028976, F32AA029288)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- alcoholism, pharmacotherapy, drug repurposing, disulfiram, acamprosate, naltrexone, nalmefene, topiramate, gabapentin, varenicline, baclofen, sodium oxybate, aripiprazole, ondansetron, mifepristone, ibudilast, suvorexant, prazosin, doxazosin, N-acetylcysteine, cannabidiol, precision medicine, treatment access, treatment seeking
- MeSH terms
- Topiramate, Acamprosate, Alcohol Deterrents, Alcoholism, Baclofen, Disulfiram, Humans, Naltrexone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.